Show simple item record

dc.contributor.authorSarı, Sezin Yüce
dc.contributor.authorYazıcı, Gözde
dc.contributor.authorYüce, Deniz
dc.contributor.authorCengiz, Mustafa
dc.contributor.authorÖzyiğit, Gökhan
dc.date.accessioned2020-02-17T11:56:06Z
dc.date.available2020-02-17T11:56:06Z
dc.date.issued2017
dc.identifier.issn1306-133X
dc.identifier.urihttps://doi.org/10.4999/uhod.171931
dc.identifier.urihttp://hdl.handle.net/11655/22153
dc.description.abstractEsophagitis is a very common toxicity of radiotherapy (RT). European Organization for the Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-OES18 can be used to measure the quality of life (QoL) associated with esophageal symptoms. We aimed to translate and validate this questionnaire in Turkish patients. Patients with head and neck cancer (HNC), lung cancer (LC) or esophageal cancer (EC) were administered the EORTC QLQ-C30 and QLQ-OES18 on the 1st, 15th, and last days of RT and at the 3rd month follow-up. Psychometric properties of reliability, validity, scale structure and responsiveness to change were analyzed. Ninety-seven patients were included in the study. All scores in the QLQ-C30, and all but the reflux scores in the QLQ-OES18 were found to change significantly during and after treatment. All correlations of the QLQ-OES18 scale between the 1st and 15th days, 15th and last days, and all but the trouble with coughing score between the last day and follow-up were significantly different. Correlation levels ranged between 33.5-79.9%, 48.7-87.2%, and 0.6-74.8% at each comparison period, respectively. The reliability was evaluated by Cronbach's alpha at each assessment period, and the result was 0.824, 0.889, 0.898, and 0.824 for treatment start, mid-treatment, treatment end, and 3rd month follow-up, respectively. The Turkish version of QLQ-OES18 is a valid tool which can be used independently from the demographic and clinical characteristics of the patients. It is highly reliable to evaluate health-related QoL in patients with esophageal symptoms that are treated for HNC, LC, or EC.tr_TR
dc.language.isoentr_TR
dc.publisherAkad Doktorlar Yayınevitr_TR
dc.relation.isversionof10.4999/uhod.171931tr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectEsophageal toxicitytr_TR
dc.subjectQuality of lifetr_TR
dc.subjectRadiotherapytr_TR
dc.subjectValidationtr_TR
dc.subject.lcshTıptr_TR
dc.titleValidation of the Eortc Qlq-Oes18 Questionnaire in Patients Treated with Radiotherapytr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.contributor.departmentoldinfo:eu-repo/semantics/publishedVersion
dc.relation.journalUhod-Uluslararasi Hematoloji-Onkoloji Dergisitr_TR
dc.contributor.departmentRadyasyon Onkolojisitr_TR
dc.identifier.volume27tr_TR
dc.identifier.issue3tr_TR
dc.identifier.startpage178tr_TR
dc.identifier.endpage184tr_TR
dc.description.indexWoStr_TR
dc.description.indexScopustr_TR
dc.fundingYoktr_TR


Files in this item

This item appears in the following Collection(s)

Show simple item record